4//SEC Filing
Hanson James S. 4
Accession 0001562180-23-000250
CIK 0001560241other
Filed
Jan 4, 7:00 PM ET
Accepted
Jan 5, 8:25 PM ET
Size
13.3 KB
Accession
0001562180-23-000250
Insider Transaction Report
Form 4
Hanson James S.
General Counsel
Transactions
- Sale
Common Stock
2023-01-05$5.41/sh−729$3,942→ 41,087 total - Sale
Common Stock
2023-01-04$5.58/sh−1,639$9,138→ 41,816 total - Award
Common Stock
2023-01-03+17,900→ 43,455 total - Award
Stock Options (Right to buy)
2023-01-03+35,700→ 35,700 totalExercise: $5.73Exp: 2033-01-03→ Common Stock (35,700 underlying)
Footnotes (9)
- [F1]Represents a restricted stock unit ("RSU") award that vests 25% on January 3, 2024 and 12.5% semi-annually thereafter, subject to the Reporting Person's continued service through each applicable vesting date.
- [F2]Each RSU represents a contingent right to receive one share of Issuer common stock.
- [F3]Represents (i) 6,680 shares of common stock; (ii) 6,875 RSUs from award granted on January 4, 2021; (iii) 12,000 RSUs from award granted on January 3, 2022; and (iv) 17,900 RSUs from award granted on January 3, 2023.
- [F4]The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell-to-cover" transaction and do not represent discretionary transactions by the Reporting Person.
- [F5]The price represents the weighted average price with a low of $5.44 and a high of $5.78. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F6]Represents (i) 8,041 shares of common stock; (ii) 6,875 RSUs from award granted on January 4, 2021; (iii) 9,000 RSUs from award granted on January 3, 2022; and (iv) 17,900 RSUs from award granted on January 3, 2023.
- [F7]The price represents the weighted average price with a low of $5.35 and a high of $5.49. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F8]Represents (i) 8,687 shares of common stock; (ii) 5,500 RSUs from award granted on January 4, 2021; (iii) 9,000 RSUs from award granted on January 3, 2022; and (iv) 17,900 RSUs from award granted on January 3, 2023.
- [F9]The shares underlying this option vest as to 25% of the shares on January 3, 2024, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date.
Documents
Issuer
G1 Therapeutics, Inc.
CIK 0001560241
Entity typeother
Related Parties
1- filerCIK 0001744887
Filing Metadata
- Form type
- 4
- Filed
- Jan 4, 7:00 PM ET
- Accepted
- Jan 5, 8:25 PM ET
- Size
- 13.3 KB